-Company to discuss launch plans for Upneeq and will be joined by Dr. Derek Cunningham, OD, FAAO-
BRIDGEWATER, N.J., Aug. 06, 2020 (GLOBE NEWSWIRE) — Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, today announced that the Company will release its 2020 second quarter financial results on Tuesday, August 11, 2020, after the close of the U.S. financial markets.
Brian Markison, Chief Executive Officer, James “JD” Schaub, Chief Operating Officer, and Andrew Einhorn, Chief Financial Officer, will host a conference call as follows:
|Date||Tuesday, August 11, 2020|
|Time||4:30 p.m. ET|
|Toll free (U.S.)||(866) 672-5029|
|Webcast (live and replay)||www.osmotica.com under the “Investor & News” section|
About Osmotica Pharmaceuticals plc
Osmotica Pharmaceuticals plc is a fully integrated biopharmaceutical company focused on the development and commercialization of specialty products that target markets with underserved patient populations. The company has a diverse portfolio consisting of four promoted products and approximately 30 non-promoted products, several of which incorporate Osmotica’s proprietary Osmodex® drug delivery system. RVL Pharmaceuticals, Inc. is the Company’s ophthalmic subsidiary supporting UPNEEQ. Vertical Pharmaceuticals, LLC represents the Company’s diversified branded portfolio and Trigen Laboratories, LLC represents the Company’s non-promoted products, including complex generic formulations.
Osmotica has operations in the United States, Argentina, and Hungary.
Investor and Media Relations for Osmotica Pharmaceuticals plc
Lisa M. Wilson
In-Site Communications, Inc.
E: [email protected]
- Investor Reminder: Kessler Topaz Meltzer & Check, LLC Reminds Investors of Splunk Inc. of Fast Approaching Deadline - January 16, 2021
- ALERT: Halper Sadeh LLP Reminds Investors of Its Ongoing Merger Investigations; Shareholders are Encouraged to Contact the Firm – CBMG, CGIX, UROV - January 16, 2021
- ROSEN, A TOP RANKED LAW FIRM, Reminds ACM Research, Inc. Investors of Important February 19 Deadline in Securities Class Action – ACMR - January 16, 2021